Notably, engineered variants of PGRN are anticipated to inhibit the degeneration process induced by TNF-α, indicating that PGRN represents a promising therapeutic target for IDD, which necessitates further investigation in human studies (66). The gene discussed is TNF; the disease is intervertebral disk degenerative disorder.